Company Overview and News
They're baaack! Actually, some of them have been back for a while, but I have not felt compelled to write about them until now. "They" are, of course, former members of my Bottom of the Barrel Club who declared bankruptcy during the past 2-3 years. The companies in this article are now trading publicly again (with 1 or 2 exceptions). I may refer to them as the "X-11 Club" occasionally.
ECR CHPE UPL GDPMQ LNGG SDRPQ DVN PVA GDAOQ VNR CHAP VNRBP GDRRQ LINEQ TALO GDPM BRMR PVAYQ VNRR HKRCP SBOW SD GDUEQ SDOCQ GDANQ GDP RVRA PVAC SGY HK MPO VNRAP TTEN MPOYQ VNRCP UPLMQ BRY GDPAN SDRXP LINE SDRXQ GDPAQ
Good day and welcome to the Goodrich Petroleum First Quarter 2018 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today's presentation, there'll be an opportunity to ask questions. [Operator Instructions] Please note this event is being recorded.
GDRRQ GDUEQ GDAOQ GDANQ GDPMQ GDP GDPM GDPAN GDPAQ
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
GDPMQ RACE PXD GDAOQ CATO GDRRQ AMC IAC PDCE SM IPXL BKE CCL ESTE BRK.A GDP CLDR GOOGL PNC FCAU BA GDPAN GDPAQ WFCNP LMT FB AIHS RCUS CPE GST-A EGY NOVN RAD BWB GST-B SLP GST LB ETH AXAS ADBE MYL SELB RYN AAPL CCL AMR DAL BBBY DIS WFC C GDPM CMCSA COST GDUEQ SIX PGEM BLK GDANQ JPM ZUMZ WRD BYD
2018-03-31 seekingalpha - 4
Every now and then the elephant in the run stomps and makes a lot of noise. Investors had better pay attention because the problem that everyone hoped would never be voiced now makes the front pages followed by potentially more stock impact.
CRC PTQEP GDPMQ CHKVP SDRPQ CHKDH CHKVZ CHKDG CHKDJ GDAOQ CHKDP GDRRQ CKRGZ GDPM HKRCP SD CHKWZ GDUEQ SDOCQ GDANQ GDP CHK CHK.WI HK GDPAN SDRXP PQ SDRXQ GDPAQ
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET